Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
FibroBiologics Inc has a consensus price target of $13.6 based on the ratings of 5 analysts. The high is $16 issued by D. Boral Capital on March 4, 2025. The low is $12 issued by HC Wainwright & Co. on February 13, 2025. The 3 most-recent analyst ratings were released by D. Boral Capital on March 4, 2025, February 27, 2025, and February 13, 2025, respectively. With an average price target of $16 between D. Boral Capital, there's an implied 1468.63% upside for FibroBiologics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/04/2025 | Buy Now | 1468.63% | D. Boral Capital | Jason Kolbert47% | $16 → $16 | Maintains | Buy | Get Alert |
02/27/2025 | Buy Now | 1468.63% | D. Boral Capital | Jason Kolbert47% | $16 → $16 | Maintains | Buy | Get Alert |
02/13/2025 | Buy Now | 1468.63% | D. Boral Capital | Jason Kolbert47% | $16 → $16 | Maintains | Buy | Get Alert |
02/13/2025 | Buy Now | 1076.47% | HC Wainwright & Co. | Matthew Caufield37% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
12/27/2024 | Buy Now | 1468.63% | D. Boral Capital | Jason Kolbert47% | $16 → $16 | Maintains | Buy | Get Alert |
12/12/2024 | Buy Now | 1076.47% | Rodman & Renshaw | Elemer Piros54% | → $12 | Initiates | → Buy | Get Alert |
11/20/2024 | Buy Now | 1468.63% | D. Boral Capital | Jason Kolbert47% | $16 → $16 | Maintains | Buy | Get Alert |
11/13/2024 | Buy Now | 1468.63% | D. Boral Capital | Jason Kolbert47% | $16 → $16 | Maintains | Buy | Get Alert |
11/13/2024 | Buy Now | 1076.47% | HC Wainwright & Co. | Matthew Caufield37% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
10/30/2024 | Buy Now | 1076.47% | HC Wainwright & Co. | Matthew Caufield37% | → $12 | Initiates | → Buy | Get Alert |
10/18/2024 | Buy Now | 1468.63% | EF Hutton | Jason Kolbert47% | $16 → $16 | Maintains | Buy | Get Alert |
09/24/2024 | Buy Now | 1076.47% | Maxim Group | Michael Okunewitch25% | → $12 | Initiates | → Buy | Get Alert |
09/13/2024 | Buy Now | 1468.63% | EF Hutton | Jason Kolbert47% | $16 → $16 | Maintains | Buy | Get Alert |
09/04/2024 | Buy Now | 1468.63% | EF Hutton | Jason Kolbert47% | → $16 | Initiates | → Buy | Get Alert |
The latest price target for FibroBiologics (NASDAQ:FBLG) was reported by D. Boral Capital on March 4, 2025. The analyst firm set a price target for $16.00 expecting FBLG to rise to within 12 months (a possible 1468.63% upside). 14 analyst firms have reported ratings in the last year.
The latest analyst rating for FibroBiologics (NASDAQ:FBLG) was provided by D. Boral Capital, and FibroBiologics maintained their buy rating.
There is no last upgrade for FibroBiologics
There is no last downgrade for FibroBiologics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of FibroBiologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for FibroBiologics was filed on March 4, 2025 so you should expect the next rating to be made available sometime around March 4, 2026.
While ratings are subjective and will change, the latest FibroBiologics (FBLG) rating was a maintained with a price target of $16.00 to $16.00. The current price FibroBiologics (FBLG) is trading at is $1.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.